BriaCell Therapeutics Corp. (NASDAQ: BCTX, BCTXL) announced development of Bria-OVA+, a personalized immunotherapy candidate for ovarian cancer treatment. The clinical-stage biotechnology company licensed ovarian cancer cell lines from American Type Culture Collection and began development activities for potential clinical use.

The immunotherapy candidate builds on the company's Bria-OTS+ platform, which previously showed results in a Phase 2 study for metastatic breast cancer. Bria-OVA+ is designed with additional immune-stimulating components intended to support anti-tumor activity.

"Following the encouraging efficacy and tolerability data from BriaCell's Phase 2 study in metastatic breast cancer, we are expanding our pipeline to include cell-based immunotherapy candidates for gynecologic cancers beginning with ovarian," stated Dr. William V. Williams, the company's President and CEO.

According to the National Cancer Institute, an estimated 21,010 women in the U.S. will be diagnosed with ovarian cancer in 2026, with approximately 12,450 expected to die from the disease. Current treatments include surgery, platinum-based chemotherapy, and targeted therapies, though many patients do not respond to available options.

BriaCell recently reported preclinical data for Bria-BRES+, another immunotherapy candidate from the same platform. In a recent poster presentation, Bria-BRES+ demonstrated activation of adaptive and innate immunity, including T cells, dendritic cells, and natural killer cells.

The information is based on a company press release.